Barbara Eichhorst, MD from the Ludwig-Maximilians University, Munich, Germany, provides an overview of combination studies presented at the American Society of Hematology (ASH) 2015 Annual Meeting held in Orlando, FL. Dr Eichhorst gives an overview of the Phase III clinical trial comparing chlorambucil with ibrutinib as front-line therapies, and an overview of the Phase II clinical trial of venetoclax in chronic lymphocytic leukaemia (CLL) patients with 17p deletion.